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Aspirin and tension-type headache




(ASA, Aspirin) is among the most
used drugs worldwide. At present,
Aspirin represents a quite versatile
drug employed in the control of
pain symptomatologies and in situ-
ations such as prevention of both
ischaemic stroke and cardiovascu-
lar events. Aspirin causes inhibi-
tion of prostaglandin (PG) synthe-
sis by inactivation of the cyclooxy-
genase (COX) enzyme. ASA con-
stitutes the focus of new researches
explaining more widely Aspirin’s
control of inflammation. The
induction of the endogenous
epimers lipoxins (Aspirin-triggered
15-epi-lipoxins, ATLs) represents
one of the most recent achieve-
ments. This particular feature of
Aspirin is not shared by other
NSAIDs. ASA is well known as a
headache medication, figuring as a
possible treatment choice in ten-
sion-type headache but also in
acute migraine attacks.
Furthermore, a new Aspirin formu-
lation with a greater rapidity of
action has been introduced. In con-
clusion, little information exists on
the subject and more studies are
required.
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Acetylsalicylic acid (ASA, Aspirin) is among the most
used drugs worldwide. Although Aspirin is recognised
as anti-inflammatory, analgesic and antipyretic, it is
presently applied in several other clinical situations.
Aspirin’s low dosage (75–100 mg) is by now consoli-
dated for secondary prevention of both ischaemic stroke
and cardiovascular events. In the acute phase, higher
dosages (>300 mg) are employed [1–3]. Besides, a pos-
sible role in the incidence reduction of colon, lung and
breast cancer and even of Alzheimer’s disease has been
suggested [4–7].
The history of this substance dates back to the earliest
times, at least to 2000 years ago. In the fifth century B.C.,
Hippocrates described the properties of a juice extracted
from the cortex of the willow tree (Salix alba), which was
able to treat pain and fever.
In 1826 two Italian chemists, Fontana and Brugnatelli,
extracted the active principle from the willow and called it
salicin. They were the first scientists who isolated the active
ingredient, even though it was in a very impure form [8].
From 1859 onwards, Kolbe and his colleagues devel-
oped a process in which salicylic acid was synthetically
obtained from salicin [9]. The Kolbe process consists of a
chemical reaction of carboxylation that adds a phenolate
to carbon dioxide of the salicylate molecular structure in
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order to form salicylic acid through treatment with sul-
phuric acid. This product is toxic in high dosages per os
and hence less tolerable.
In 1897 Felix Hoffman determined a stable and more
tolerable form by combining acetylating salicylic acid
with acetic acid, in this way obtaining ASA. Hoffman was
motivated in his studies by his wish to treat his father’s
arthritis without producing stomach irritation, which
drugs at that time caused, including salicylic acid.
In 1899 ASA was registered under the trademark
Aspirin [10]. More than 70 years later, as Aspirin already
represented the most used analgesic, antipyretic and anti-
inflammatory substance in the world, Vane and his group
discovered the mechanism of the action of Aspirin-like
drugs [11]. Vane’s research on Aspirin-like drugs gained
him the Nobel Prize for Medicine in 1982.
Mechanism of action
Aspirin causes the irreversible inhibition of cyclooxyge-
nase activity (COX), defined also as endoperoxide H syn-
thase-1, by acetylation of a specific serine at the active
site of the enzyme [12]. COX activity produces the for-
mation of important mediators called protanoids including
prostaglandin, prostacyclin and thromboxane. The process
occurs via selective acetylation of a hydroxyl group of a
serine residue (Ser 530), located 70 amino acids from the
C terminus protein [13]. The inhibition of prostaglandin
(PG) formation is caused by the preclusion of arachidonic
acid (AA) binding at this site [14]. COX converts AA (a
polyunsaturated fatty acid present in the membranes phos-
pholipids of the cells) to prostaglandin G2 (PGG2), which
becomes metabolised by specific synthases, or not enzy-
matically into individual eicosanoids.
At present, we know three different COX isoforms.
COX-1 is the constitutive isoform involving physiological
processes such as gastric mucosa protection, platelet
aggregation and kidney function [15]. COX-2 is induced
by various stimuli such as mitogens, growth factors, can-
cer promoters and lipopolysaccharide, and constitutes the
principal cause of PG synthesis during inflammatory reac-
tions [16]. COX-2 was originally considered exclusively
an “inducible” isoform, but it has proved to be constitu-
tively expressed in several tissues including CNS, kidney
and megakaryocytes [17–19].
COX-3 is a COX-1 variant, inhibited by aceta-
minophen and other analgesics/antipyretic drugs. COX-3,
described as two smaller COX-1-derived proteins (partial
COX-1 or PCOX-1 proteins), is produced by the COX-1
gene but with retention of intron 1 preventing translation
and nuclear export of mRNA [20]. After Vane’s discovery,
several studies added new explanations on Aspirin’s
inflammation control.
PG inhibition constitutes Aspirin’s principal mecha-
nism of action, as a result of COX acetylation. However,
COX-2 acetylated isoform is not really inhibited but is
still active because of a larger active site and as a conse-
quence of an unusual L-shaped binding of AA within the
COX-2 substrate channel [21]. In fact, this enzyme redi-
rects the catalytic activity from intermediate generation in
a pathway of PGs and thromboxane (TX) to conversion of
AA to 15(R)-hydroxyeicosatetraenoic (15R-HETE).
Subsequently, 15R-HETE is rapidly metabolised by
leukocyte 5-lipoxygenase to generate 15 epi-LXA4 or 15
epi-LXB4 [22]. These epimers of lipoxin A4 are named
Aspirin-triggered 15-epi-lipoxin A4 and B4 (ATLs).
Therefore, Aspirin has a direct impact on lipoxygenase
interaction products (lipoxins, LX). Both LX circuit and
Aspirin-triggered biosynthesis of endogenous epimers of
LX play an important role as mediators of key events in
endogenous anti-inflammation and resolution. Differently
from other NSAIDs, this new mechanism of action repre-
sents an exclusive property of Aspirin [23]. This suggests
a main role not only in the inhibition of pro-inflammatory
mediators, but also in the induction of endogenous anti-
inflammatory factors [24].
15-epi-lipoxin A4 production in humans also depends
on a low daily Aspirin dosage (81 mg) exerting an anti-
inflammatory action through local production of 15-LXs.
This has been documented in a randomised human trial of
healthy volunteers conducted by Chiang et al. [25].
Furthermore, ATLs elicit nitric oxide (NO) synthesis
from both constitutive (eNOS) and inducible NO synthase
(iNOS). In fact Aspirin, but not other NSAIDs, increases
plasma NO [26, 27].
Paul-Clark et al. [28] report the inhibition of acute
inflammation by Aspirin depending on induction of plas-
ma NO, which negatively regulates leukocyte–endotheli-
um interaction in the microcirculation. This experiment
shows Aspirin was not anti-inflammatory in NOS knock-
out mice with IL-1β-induced peritonitis.
Aspirin and headache
The 1-year period prevalence of migraine in adults has
been found around 10%–12%, 6% in men and 15%–18%
among women, while 59% of people experiences tension-
type headache (TTH) at least 1 day per month [29]. TTH
prevalence was related to age, while migraine showed no
correlation to it within the studied age interval.
TTH represents the most frequent headache form,
involving 82% of headache sufferers, while 14% of this
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population is affected by migraine and 4% by a chronic
form (chronic daily headache, CDH) [30].
Self-medication constitutes the most common treat-
ment. Among headache sufferers, 91% of TTH patients
and 90% of migraine patients use non-narcotic, over-the-
counter (OTC) analgesics, which are often taken without
any other form of treatment and without consulting a
physician [31].
A community-based telephone survey showed that
98% of TTH sufferers depend on OTC medication. At
least one dose of this kind of medication was taken, with
no difference between males and females. A third of
patients was remedicated. Acetaminophen constituted the
most used drug (56%), followed by ASA (15%) and
ibuprofen (9%) [32]. ASA remains among the most impor-
tant and well known treatments in headache management
[33]. However, the time of administration remains a point
of debate.
The common strategy employed for migraine attacks is
prompt treatment [34]. Triptans, drugs like NSAIDs and
ergotamine respond to this strategy [35]. In the early treat-
ment of migraine, OTC medications are largely used as
they do not require a medical prescription and are easily
available. A combination of OTC medications (Aspirin
500 mg, acetaminophen 500 mg and caffeine 130 mg) has
been compared to a prescription migraine product (suma-
triptan 50 mg), underlining a significant efficacy of this
association in early migraine abortive treatment [36]. A
similar approach has not been investigated yet in TTH, but
pain relief as a result of rapid intake seems a reasonable
suggestion. In addition, OTC medications have other
advantages, such as the absence of cardiovascular contra-
dictions, which are present in triptans. Moreover, OTC
drugs could reduce medication costs [37, 38].
On the other hand, Aspirin and other NSAIDs show
infrequent limitations. The incidence of upper gastroin-
testinal tract complications (i.e., bleeding or perforation)
in the general population is estimated to be 1–2 cases per
1000 persons/year, with a case fatality rate ranging from
5% to 10%. These results can be found in observational
studies involving patients in long-term use of low-dose
Aspirin for prevention of cardiovascular diseases [39, 40].
Major and minor bleeding complications can occur as well
[41]. Aspirin-induced asthma constitutes another rare but
possible immediate adverse event [42].
Aspirin and migraine
The pathophysiological mechanisms of migraine have
been analysed in depth [43] and Aspirin represents, in the
treatment of acute migraine attacks, a possible therapeutic
choice. Extensive literature exists regarding both its effi-
cacy and safety. Different dosages, formulations and asso-
ciations with other drugs have been investigated in vari-
ous randomised, double-blind, placebo-controlled studies.
Compared to placebo, Aspirin was more effective in
reducing headache from severe to mild or in achieving
pain relief 1 h after administration [44]. A range of ASA
dosages between 650 and 1000 mg proved to be consid-
erably more successful for pain reduction than placebo
[45]. No statistically significant differences were found
between Aspirin and placebo for nausea, vomiting or
phonophobia, except in a study conduced by MacGregor
et al. [46]. Aspirin’s tablet and effervescent versions dis-
played the same efficacy in this study.
Aspirin is safe and well tolerated. In fact, adverse
events of ASA were mild or moderate and similar to
placebo responses (8.3% vs. 2.9%) [47]. In the treatment
of migraine attacks, 1000 mg effervescent ASA was as
effective as 50 mg sumatriptan or 400 mg ibuprofen and
all these treatments were superior to placebo (p<0.0001).
However, sumatriptan was more effective than ASA in
the pain-free response 2 h after administration [48].
Aspirin (650 mg) combined with metoclopramide (10
mg), a dopamine antagonist producing a direct effect on
the gastrointestinal tract, proved to be as functional as
Aspirin alone. Both were more effective than placebo. No
significant differences were found with regard to anti-
nausea effects [49, 50].
The efficacy of Aspirin (1000 mg) and a combination of
acetaminophen 400 mg and codeine 25 mg showed not sig-
nificant differences in their activity [51]. At last, a possible
role for a low dosage of Aspirin has been suggested in
migraine prophylaxis [52].
Aspirin and tension-type headache
The pathophysiological mechanism of TTH has been well
investigated, but with little definitive evidence regarding
its acute treatments. This is mainly due to the paucity of
existing targets in its putative pathophysiological cascade
[53, 54]. In the past, peripheral factors have been consid-
ered to be leading factors. In a study comparing a group of
patients affected by TTH with a healthy control group,
Langemark and Olesen observed an increase in tenderness
inside the pericranial muscles [55]. It is not clear if muscle
factors, although important, represent a cause or an effect
of pain, as they could be involved in the development of
central sensitisation through the input from myofascial
nociceptors [56]. The sensitisation of peripheral nocicep-
tors is explained by the increased pain response in patients
affected by episodic TTH. In an experimental human
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model of myofascial pain, the infusion of a combination of
bradykinin (BK), serotonin [5-hydroxytryptamine (5-HT)],
histamine (His) and prostaglandin E2 (PGE2) into the
trapezius muscle induces prolonged pain in both patients
and controls. Furthermore, patients report a pronounced
sensitivity to pain, possibly indicating a peripheral
increased excitability or sensitisation in patients with
episodic tension headache [57].
Besides, the excitability reduction of brain stem
interneurons in TTH patients suggests the possible defi-
cient endogenous pain control mechanisms by recording
the blink reflex recovery cycle and the exteroceptive sup-
pression of temporalis muscle activity [58].
At present, central factors apparently play a central
role in TTH, principally in chronic forms [59]. According
to this hypothesis, the central sensitisation at the spinal
dorsal horn/trigeminal nucleus level is given by prolonged
nociceptive input from pericranial myofascial tissues.
This nociceptive input may result in a secondary sensiti-
sation of supraspinal neurons [60].
Aspirin is useful for acute pain-relief therapy because
it is inexpensive, easily available and does not require a
medical prescription. Unlike other treatments, a small
number of randomised, double-blind, placebo-controlled
studies have been carried out. However they demonstrate
Aspirin’s efficacy in TTH.
Steiner et al. [61] display the statistical difference in
terms of efficacy of Aspirin 1000 mg (75.7%; response
rate; p=0.0009) and 500 mg (70.3%; p=0.011) compared
to placebo (54.5%).
In this study paracetamol 1000 mg (71.2%; p=0.007)
results are generally similar to those of Aspirin 500 mg,
unlike paracetamol 500 mg (63.8%; p=0.104), which
proved to be not statistically different from placebo.
Differences between Aspirin 1000 mg and placebo were
significant (p≤0.022) after the first 30 min.
Aspirin’s adverse events involved 3.9%–7.2% of sub-
jects, 4.5%–5.7% for paracetamol and 1.8% for placebo,
not considering dose correlation in the latter two drugs.
However all events were mild and transient.
Aspirin’s effectiveness compared to placebo has also
been demonstrated by Peters et al. [62]. The same results
can be also found in a double-blind, placebo-controlled
study by Langemark and Olesen. In this study, ASA, in
both solid and effervescent forms, was tested, but no sta-
tistical difference could be observed [63].
Aspirin’s new formulation
Headache therapy and the role of Aspirin have not been
sufficiently investigated. However, acute attack thera-
py must converge on high efficacy and fast onset of
action.
At present, a new Aspirin formulation with a faster
bioavailability is making its debut. The new Aspirin is
composed of dry granules containing 500 mg of ASA.
This new formulation is moderately effervescent and
mouth dispersible after administration onto the tongue,
without water. This administration pathway permits a
more rapid passage through the stomach to the small
bowel (main site of ASA adsorption).
Mouth dispersion does not damage the dental enamel.
Reduced exposure (max. 30 s) does not cause erosion of
the dental surface.
In a randomised, not blinded, cross-over study, Latta et
al. [64] demonstrated the faster onset of action of this new
formulation with respect to standard ASA tablets.
Maximal ASA plasma concentrations are higher with
respect to plain Aspirin tablets (Fig. 1). In this study, the
value of Cmax (maximal plasmatic concentration) of ASA
granules is about 50% higher compared to ASA plain
tablets (Table 1). Also, the highest concentration is
reached already after 20 min, while the standard formula-
tion takes 30 min (Fig. 1).
ASA’s relative bioavailability was found to be 118 (CI
1.03–1.34), significantly higher than plain tablets. A sim-
ilar analysis is also possible for salicylic acid, the princi-
pal metabolite of ASA (Fig. 2). Adverse events are similar
in both treatments.
In conclusion, the new formulation’s rapidity of
action could represent a choice for prompt treatment of
TTH, especially concerning episodic attacks. The use of
Aspirin at the beginning of attacks could be a possible
pain-relief treatment, which should be investigated in
larger studies.
Fig. 1 Plasma concentration vs. time curves for ASA (geometric
mean including 1 SD range)
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Conclusions
The literature concerning Aspirin in the treatment of TTH
is not totally satisfying, while more information exists
concerning acute migraine treatment. Considering the
large population affected by episodic TTH [65], a treat-
ment that is rapid, effective, low-cost and does not require
a medical prescription may constitute a binding choice. In
such cases, effectiveness and a rapid pain-relief action
become essential. Therefore, Aspirin could represent a
useful treatment option in TTH, as already shown in acute
migraine attack.
The definitive understanding of the pathophysiological
mechanics of TTH will offer, in the near future, the basis
for new therapeutic opportunities. At present, more stud-
ies dealing with this topic are necessary.
Table 1 Geometric means/geometric standard deviations of ASA pharmacokinetic characteristics in plasma following a single dose
administration of two ASA formulations
Parameter Unit Granules 500 mg (test) Plain tablet 500 mg (reference)
Cmax mg/L 5.34/1.27 3.63/1.94
Cmax,norm kg/L 0.85/1.24 0.58/1.92
tmax# h 0.33 (0.33–1.0) 0.50 (0.33–2.0)
AUC mg*h/L 4.97/1.19 4.25/1.53
AUCnorm kg*h/L 0.79/1.18 0.68/1.51
MRT h 0.80/1.26 1.11/1.56
frel % 118 (90% CI: 1.03–1.34) 100
t1/2 h 0.35/1.16 0.51/1.72
# Median (range)
Fig. 2 Plasma concentration vs. time curves for SA (geometric
mean including 1 SD range)
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